Organic Acids Test (OAT): A Naturopathic Guide to Interpretation and Clinical Application

A clinician-facing guide to the Organic Acids Test (OAT) — covering urine metabolomics methodology, key marker categories (gut dysbiosis, mitochondrial function, neurotransmitter metabolism, nutrient cofactors, detoxification, oxalates), how to order in Australia, and clinical workflow integration.

Educational disclaimer: This article is written for health professionals and informed practitioners in naturopathic and integrative clinical settings. It does not constitute individual medical advice. All findings from functional metabolic testing require clinical interpretation by a qualified practitioner. No supplement or treatment protocol described here should be initiated without individual assessment.

The Organic Acids Test (OAT) is one of the more informationally dense panels available in functional and naturopathic medicine — and one of the most underutilised. A single first-morning urine sample yields a metabolomics profile spanning gut microbiome activity, mitochondrial energy production, neurotransmitter metabolism, detoxification capacity, methylation status, and nutrient cofactor sufficiency. For practitioners who know how to read it, the OAT offers a window into cellular biochemistry that no standard serum panel can replicate.

This guide walks through the major OAT marker categories, their clinical significance, and how to translate results into a coherent treatment strategy.

What the OAT Is — and Why Urine?

The OAT is a urine-based metabolomics panel that measures 70 or more organic acid metabolites — small carbon-containing molecules produced as by-products of cellular biochemical processes. These compounds are excreted in urine at concentrations that reflect the activity — and dysfunction — of the metabolic pathways that generate them.

The choice of urine as the sample matrix is not incidental. Serum panels measure what is circulating at a given moment; urine captures what the body is actively excreting and metabolising over time. Many clinically significant organic acids are rapidly cleared from the bloodstream and reach meaningful concentrations only in urine. This makes the OAT particularly sensitive to:

Microbial metabolite production in the gut: Bacteria and fungi produce characteristic organic acids that are absorbed into the portal circulation and excreted renally. Elevated microbial-derived metabolites in urine directly reflect gut microbiome activity — often with more specificity than stool-based testing alone.
Mitochondrial pathway status: The citric acid (Krebs) cycle produces a cascade of organic acid intermediates. Elevations or depletions in these intermediates map directly to blockages or inefficiencies in mitochondrial energy production.
Cofactor-dependent enzyme function: Many of the pathways assessed by the OAT depend on specific B vitamin and mineral cofactors. When those cofactors are deficient, the relevant metabolic step stalls and upstream organic acids accumulate — producing a measurable signal in urine even before conventional serum markers become abnormal.

This is the OAT's most important clinical advantage: it detects functional insufficiency at the cellular level before deficiency is severe enough to alter serum concentrations. A patient with normal serum B12 may still show elevated methylmalonate on OAT — indicating that B12 is present in circulation but insufficient for cellular enzyme function.

Key Marker Category 1: Gut Dysbiosis Markers

The gut dysbiosis section of the OAT is frequently the most immediately actionable part of a report. Dysbiotic organisms — including bacteria, yeast, and fungi — produce metabolic by-products that are absorbed from the gut into systemic circulation and excreted in urine. The OAT captures these signatures with high specificity.

Arabinose — Yeast and Candida Overgrowth

Arabinose is a pentose sugar derivative produced by Candida species and other yeast during fermentation in the gastrointestinal tract. Elevated urinary arabinose is the OAT's primary marker for intestinal yeast overgrowth. In clinical practice, it is commonly elevated in patients with:

History of repeated antibiotic courses (which deplete bacterial competitors of Candida)
High refined carbohydrate and sugar diets
Immunosuppression or chronic corticosteroid use
Symptoms of bloating, fatigue, brain fog, and sugar cravings — the classic Candida symptom cluster

Importantly, arabinose may be elevated in the absence of any positive findings on conventional stool culture — because standard culture does not reliably detect intestinal Candida at clinically significant levels. The OAT provides this information indirectly but systematically via the metabolic signature.

HPHPA — The Clostridia Marker

3-(3-Hydroxyphenyl)-3-hydroxypropionic acid (HPHPA) is arguably the single most clinically significant dysbiosis marker on the OAT. It is produced by Clostridium species — specifically those capable of converting dopamine to a metabolite that feeds into the HPHPA pathway.

The clinical significance of elevated HPHPA extends beyond gut dysbiosis: Clostridium species that produce HPHPA also produce dopamine-degrading enzymes that reduce functional dopamine availability in the gut-brain axis. The associations documented in research literature include:

Behavioural and neurological symptoms: HPHPA elevation has been reported in association with attention dysregulation, irritability, hyperactivity, and autistic spectrum presentations. William Shaw at the Great Plains Laboratory has published extensively on this marker's clinical correlations.
Dopamine dysregulation: The HPHPA pathway competes with and impairs dopamine signalling. Patients with elevated HPHPA and complaints of low motivation, poor reward response, or mood instability warrant attention to this dysbiosis driver as a potential upstream contributor.
Neuroinflammation: Clostridium species that produce HPHPA also generate p-cresol, a phenolic compound with direct neurotoxic activity at elevated concentrations.

Clinically, elevated HPHPA is a strong signal for targeted antimicrobial intervention — typically vancomycin (antibiotic) in severe cases under medical supervision, or herbal antimicrobials with established Clostridium activity (berberine, allicin, caprylic acid) in naturopathic practice. Recurrence is common without addressing the ecological conditions that permitted Clostridium overgrowth — particularly low commensal bacterial diversity.

Benzoic Acid and Hippuric Acid

Benzoic acid is a bacterial metabolic by-product generated from phenylalanine by dysbiotic gut flora. Elevated benzoic acid is a general marker of bacterial dysbiosis — less specific than HPHPA but useful as a pattern confirmation. Hippuric acid is the glycine conjugate of benzoic acid, formed during Phase 2 liver detoxification. When both are elevated, it suggests both active bacterial dysbiosis and adequate (or overloaded) glycine conjugation capacity in the liver. When benzoic acid is elevated but hippuric acid is not, glycine conjugation may be insufficient — a secondary finding with supplementation implications.

Key Marker Category 2: Mitochondrial Function Markers

The citric acid cycle (Krebs cycle) is the central hub of cellular energy production. Each step in the cycle generates an organic acid intermediate: citrate, isocitrate, alpha-ketoglutarate, succinate, fumarate, malate, and oxaloacetate. These intermediates are normally present in small, balanced amounts in urine. When mitochondrial function is impaired — whether by toxin exposure, nutrient cofactor deficiency, or genetic enzyme variants — specific intermediates accumulate while others deplete, creating a diagnostic pattern.

Citric Acid Cycle Intermediate Patterns

Elevated succinate: Succinate dehydrogenase (complex II of the mitochondrial electron transport chain) requires riboflavin (FAD) as a cofactor and is sensitive to heavy metal inhibition (mercury, arsenic). Elevated succinate in isolation often indicates B2 insufficiency or environmental toxin exposure. In patients with fatigue and multiple chemical sensitivity, an elevated succinate-to-fumarate ratio warrants both B2 repletion and heavy metal exposure history.

Elevated citrate: High citrate can indicate impaired aconitase activity — an enzyme that depends on iron-sulfur clusters and is among the most sensitive mitochondrial enzymes to oxidative stress and heavy metal disruption. Elevated citrate in the context of other cycle elevations suggests a diffuse mitochondrial impairment rather than an isolated step blockage.

Elevated malate and fumarate: When multiple Krebs cycle intermediates are elevated simultaneously, this pattern suggests a broad energy production deficit — often seen in chronic fatigue presentations, post-viral syndromes, and patients with significant toxic burden. This is the OAT pattern most consistent with clinically recognised mitochondrial dysfunction.

Pyruvate and Lactate

Pyruvate and lactate sit at the entry point to the Krebs cycle. Pyruvate is normally converted to acetyl-CoA by the pyruvate dehydrogenase complex (PDC), which requires thiamine (B1), lipoic acid, CoA (from pantothenic acid/B5), and magnesium. When PDC is impaired, pyruvate accumulates and is shunted to lactate via lactate dehydrogenase.

Elevated urinary lactate with elevated pyruvate suggests PDC dysfunction — commonly from B1 or lipoic acid deficiency, heavy metal inhibition of PDC subunits, or high carbohydrate loads in a mitochondrially compromised patient. An elevated lactate-to-pyruvate ratio (>20:1) in the context of clinical fatigue is a significant finding warranting specific mitochondrial support.

Naturopathic mitochondrial support for elevated cycle intermediates:

Thiamine (B1): 100–300 mg daily; benfotiamine (fat-soluble form) for central nervous system access
Riboflavin (B2): 100–400 mg daily; riboflavin-5-phosphate for direct cofactor availability
Alpha-lipoic acid: 300–600 mg daily; cofactor for PDC and alpha-ketoglutarate dehydrogenase
CoQ10 as ubiquinol: 200–400 mg daily; essential electron carrier in the respiratory chain — the CoQ10 and ubiquinol clinical comparison is relevant here, as the reduced ubiquinol form is preferred in patients with compromised mitochondrial reduction capacity
Magnesium malate: 300–400 mg daily; magnesium is an ATP cofactor; malate directly feeds the cycle at the fumarase step

Key Marker Category 3: Neurotransmitter Metabolism Markers

The OAT includes metabolites that reflect the downstream processing of three major neurotransmitter systems: dopaminergic, adrenergic, and serotonergic. These are not direct neurotransmitter measurements — they are metabolic by-products that appear in urine after central and peripheral neurotransmitter turnover. Their clinical value lies in identifying patterns of excess or deficient neurotransmitter activity.

HVA — Dopamine Metabolite

Homovanillic acid (HVA) is the primary urinary metabolite of dopamine, produced via catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Elevated HVA suggests high dopamine turnover — which may occur with stress, stimulant use, or in compensatory response to dopamine receptor downregulation. Low HVA suggests reduced dopamine synthesis or turnover — associated with fatigue, low motivation, depression, and cognitive sluggishness.

HVA should be interpreted alongside HPHPA: when HPHPA is elevated and HVA is low, the Clostridium dysbiosis pattern is interfering with dopamine metabolism — a gut-brain axis connection that often manifests as mood and behavioural symptoms without an obvious psychiatric trigger.

VMA — Adrenaline and Noradrenaline Metabolite

Vanillylmandelic acid (VMA) is the primary urinary metabolite of epinephrine and norepinephrine. Elevated VMA indicates high catecholamine turnover — consistent with chronic sympathetic activation, HPA axis overactivation, or adrenal medullary stress. Low VMA in the context of fatigue and poor stress response suggests depleted catecholamine production — a burnout pattern. The HVA:VMA ratio is sometimes used to assess dopaminergic vs. adrenergic balance; an imbalanced ratio may inform neurotransmitter precursor support strategy.

5-HIAA — Serotonin Metabolite

5-hydroxyindoleacetic acid (5-HIAA) is the primary urinary metabolite of serotonin, produced by MAO-mediated oxidation. Elevated 5-HIAA can indicate high serotonin turnover — sometimes associated with gut inflammation, as approximately 95% of the body's serotonin is produced by enterochromaffin cells in the gut wall. Persistently and markedly elevated 5-HIAA warrants consideration of carcinoid pathology and clinical follow-up. Low 5-HIAA is consistent with reduced serotonin synthesis — potentially signalling tryptophan deficiency, inadequate cofactors (iron, B6, zinc for tryptophan hydroxylase), or the tryptophan shunting described below.

Quinolinic Acid — The Neuroinflammation Marker

Quinolinic acid is a tryptophan metabolite produced via the kynurenine pathway — a competing branch to serotonin synthesis. Under conditions of immune activation and neuroinflammation, the enzyme indoleamine 2,3-dioxygenase (IDO) is upregulated, shunting tryptophan away from serotonin production and toward quinolinic acid synthesis.

Quinolinic acid is an NMDA receptor agonist with excitotoxic properties — it over-stimulates glutamate receptors, contributing to neuronal damage, oxidative stress, and mitochondrial dysfunction in neurological tissue. Elevated quinolinic acid is found in conditions including:

Neurological autoimmune conditions
Post-infectious neuroinflammation (including post-viral fatigue syndromes)
Active gut inflammation with systemic immune activation
Depression with an inflammatory substrate

When quinolinic acid is elevated, the clinical response involves addressing the upstream inflammatory driver rather than supplementing serotonin precursors — adding tryptophan without resolving the IDO-upregulating inflammation simply generates more quinolinic acid. Anti-inflammatory strategies, gut repair, and downstream support with NAD+ precursors (to redirect kynurenine pathway metabolites productively) are the appropriate clinical response.

Key Marker Category 4: Nutrient Cofactor Status Markers

Methylmalonate — Functional B12 Status

Methylmalonyl-CoA mutase is a B12-dependent enzyme that converts methylmalonyl-CoA to succinyl-CoA in the Krebs cycle. When B12 is functionally insufficient at the cellular level, this step is impaired and methylmalonate accumulates in urine.

Urinary methylmalonate is the most sensitive functional indicator of B12 deficiency currently available — it reflects intracellular B12 availability rather than serum B12 levels. A patient may have a serum B12 of 400 pmol/L (within the conventional normal range) and still show elevated OAT methylmalonate, indicating that B12 is not adequately reaching the cellular level where it is needed. This is particularly relevant in:

Patients with MTHFR or other methylation polymorphisms affecting B12 processing
Elderly patients (gastric atrophy reduces intrinsic factor and B12 absorption)
Long-term metformin users (metformin impairs B12 absorption)
Vegetarians and vegans
Patients with gut permeability or malabsorption

Clinical response to elevated methylmalonate: methylcobalamin supplementation (1000–2000 mcg sublingual daily), which bypasses intrinsic factor-dependent absorption, or if severely elevated, intramuscular B12 injection under medical supervision.

Xanthurenic Acid — Functional B6 Status

Xanthurenic acid is produced when the tryptophan-to-kynurenine metabolic step is impaired due to B6 (pyridoxal-5-phosphate) deficiency. Kynureninase, the enzyme responsible for this conversion, is a B6-dependent enzyme — when B6 is insufficient, kynurenine accumulates and is shunted to xanthurenic acid.

Elevated xanthurenic acid on OAT is a reliable functional indicator of B6 insufficiency — again, often seen before serum B6 falls below the conventional reference range. B6 deficiency impairs not only tryptophan metabolism but also dopamine synthesis (dopa decarboxylase is B6-dependent), GABA synthesis (glutamic acid decarboxylase is B6-dependent), and histamine metabolism (DAO enzyme requires B6). The breadth of B6-dependent pathways makes xanthurenic acid elevation a clinically important and frequently actionable finding.

Clinical response: pyridoxal-5-phosphate (P5P, the active form) at 25–50 mg daily; avoid high-dose pyridoxine (the inactive form) in patients with known neuropathy risk.

Pantothenate Markers

Pantothenic acid (B5) is a precursor to coenzyme A (CoA) — required at multiple steps in the Krebs cycle, fatty acid metabolism, and acetylcholine synthesis. Elevated markers of impaired CoA-dependent reactions on OAT suggest functional B5 insufficiency, though this is a less common finding than B12 or B6 markers in most clinical populations.

Key Marker Category 5: Detoxification and Oxidative Stress Markers

Pyroglutamate

Pyroglutamate (5-oxoproline) accumulates when glutathione synthesis is impaired. The gamma-glutamyl cycle that produces glutathione generates pyroglutamate as a by-product; normally it is efficiently recycled back to glutamate. When glutathione demand is high (chronic oxidative stress, significant toxic burden) or when glutathione precursor availability (cysteine, glycine, glutamate) is insufficient, pyroglutamate accumulates.

Elevated pyroglutamate signals oxidative stress and glutathione depletion — a clinically relevant finding in patients with chronic illness, high toxic exposure, or significant dietary protein restriction. N-acetylcysteine (NAC, 600–1200 mg daily), glycine, and selenium (as selenomethionine) support glutathione synthesis and recycling.

8-Hydroxy-2-deoxyguanosine (8-OHdG)

8-OHdG is a product of oxidative DNA damage — formed when reactive oxygen species attack guanine bases in DNA. Its presence in urine reflects the rate of oxidative damage to nuclear and mitochondrial DNA. Elevated 8-OHdG is one of the most direct markers of systemic oxidative burden available in clinical metabolomics, and is associated with accelerated biological ageing, mitochondrial dysfunction, and increased risk of degenerative conditions.

Clinical response: broad-spectrum antioxidant support, identification and reduction of oxidative drivers (smoking, alcohol, heavy metal exposure, chronic infection, dietary advanced glycation end-products), and addressing mitochondrial dysfunction that generates excessive superoxide.

Sulfate

Urinary sulfate reflects the activity of the sulfation pathway — a major Phase 2 detoxification route for phenols, steroids, neurotransmitters, and xenobiotics. Low urinary sulfate in the context of elevated phenolic compounds (benzoate, p-cresol, HPHPA) suggests sulfation capacity is being outpaced by toxic load — a pattern seen in patients with environmental sensitivity and chemical intolerance. Molybdenum (75–150 mcg daily) and dietary sulfur amino acids (from eggs, legumes, alliums) support sulfation capacity.

Key Marker Category 6: Oxalate Markers

Oxalic Acid, Glycolic Acid, and Glyceric Acid

The OAT includes three oxalate-related markers that together distinguish between primary metabolic oxalate overproduction and gut-derived (secondary) oxalate elevation.

Oxalic acid (oxalate): The primary marker. Elevated urinary oxalate causes kidney stone risk, promotes calcium oxalate crystal deposition in soft tissues, and — notably — impairs mitochondrial function by depleting glutathione in mitochondrial membranes. Symptoms associated with high oxalate burden include joint pain, fibromyalgia-like pain patterns, vulvodynia, and recurrent kidney stones.

Sources of elevated oxalate via the gut dysbiosis pathway:

Candida and other gut dysbiosis organisms can generate oxalate as a metabolic by-product
Antibiotic depletion of Oxalobacter formigenes — a gut bacterium that degrades dietary oxalate — removes a major protective mechanism, allowing dietary oxalate to be absorbed rather than excreted in stool
SIBO and gut dysbiosis alter oxalate-metabolising bacterial populations and increase intestinal permeability, allowing higher dietary oxalate absorption across a permeable gut lining

Glycolic acid and glyceric acid distinguish the mechanism. Elevated glycolic acid alongside elevated oxalate (with normal glyceric acid) suggests excess oxalate from Candida or dietary sources. Elevated glyceric acid with elevated oxalate suggests a primary metabolic pathway abnormality (glyoxylate metabolism impairment). Glyceric acid elevation specifically points toward B6 cofactor deficiency as a driver, since alanine-glyoxylate aminotransferase is B6-dependent.

Clinical approach to elevated oxalates:

Address the gut dysbiosis source (arabinose and HPHPA findings guide this)
Low-oxalate dietary modification as a transitional measure
Calcium citrate with meals (binds dietary oxalate in the gut, preventing absorption)
B6 (P5P) supplementation (supports glyoxylate detoxification)
Restore Oxalobacter-supportive gut conditions through dietary prebiotic fibre and dysbiosis treatment

How to Order the OAT in Australia

The OAT is not available through Medicare or standard pathology providers — a gap that reflects broader preventive health funding policy limitations that leave functional metabolic testing outside the public system. In Australia, several pathways exist for accessing the test:

Great Plains Laboratory (USA): The original OAT provider, offering the most comprehensive marker set (70+ analytes). Requires a practitioner order. Samples are collected in Australia with a provided kit, then shipped to the US laboratory. Turnaround is typically 2–3 weeks. Cost: approximately AUD $350–$500 depending on the kit version and current exchange rates. Requires a functional medicine practitioner, naturopath, or integrative physician to order.

Nutripath Integrative Pathology Services: An Australian-based functional pathology provider that offers an organic acids profile. Shorter turnaround than US-based laboratories; cost varies by panel version. Available to naturopaths, nutritionists, and integrative practitioners.

Healthscope Functional Pathology: Offers a urine organic acids panel through their functional testing range. Australian laboratory processing; accessible to naturopaths and integrative practitioners.

SciMedics: Another Australian option for functional metabolic testing including organic acids panels.

In Australia, most functional laboratories accept orders from naturopaths, nutritionists, and integrative medicine practitioners — the patient cannot self-order. Patients should be advised to collect first-morning urine (highest concentration, most consistent across days), and to avoid vitamin C supplementation and most herbal antimicrobials for 48–72 hours prior to collection, as these can artificially alter some organic acid levels. Fasting from the evening before collection is standard protocol.

Interpreting HPHPA: The Most Clinically Significant Dysbiosis Marker

HPHPA deserves expanded clinical attention because its implications extend beyond gut health into neurology and psychiatry — and because it is frequently overlooked by practitioners unfamiliar with the OAT.

The mechanism: specific Clostridium species (particularly C. sporogenes, C. caloritolerans, and related organisms) convert dietary tyrosine and dopamine to HPHPA via hydroxyphenylacetic acid intermediates. These same organisms secrete enzymes that deaminate dopamine in the gut, reducing the pool of dopamine available for the enteric nervous system and — via systemic pathways — potentially influencing central dopaminergic tone.

Clinically significant HPHPA elevation has been documented in association with:

Autistic spectrum presentations (Shaw WR, Great Plains Laboratory research)
Psychotic episodes (case reports of HPHPA elevation during florid psychosis with improvement following antibiotic treatment)
Attention dysregulation and hyperactivity
Fatigue with cognitive impairment
Treatment-resistant depression with a gut-origin hypothesis

The co-occurrence of elevated HPHPA with elevated quinolinic acid (tryptophan shunting), low HVA (reduced dopamine metabolite), and low 5-HIAA (reduced serotonin metabolite) creates a neurological dysbiosis signature that practitioners should recognise as a pattern requiring gut-first intervention — not psychotropic prescribing in isolation.

Treatment protocol for elevated HPHPA:

Identify Clostridium speciation where possible via stool PCR (GI-MAP includes C. difficile; broader speciation may require separate testing)
Targeted antimicrobial intervention — naturopathic approach: berberine (500 mg three times daily with food), allicin (standardised garlic extract), caprylic acid (1200–2400 mg daily)
Support re-colonisation with Lactobacillus and Bifidobacterium species that competitively exclude Clostridium
Address dietary substrate — Clostridium ferments dietary protein; high-protein diets without adequate fibre create conditions that favour expansion
Retest OAT at 2–3 months to confirm HPHPA reduction

OAT Limitations: What the Test Cannot Do

Clinical honesty requires acknowledging the OAT's limitations:

Single-time-point snapshot: Organic acid levels fluctuate with diet, stress, hydration, and gut transit time. A single OAT result may not represent a patient's typical biochemistry. Where results are ambiguous, a second collection under standardised conditions improves reliability.

Dietary interference: High-dose vitamin C supplementation falsely elevates oxalate markers. Recent antibiotic use suppresses microbial organic acid production, potentially masking dysbiosis. A high-sugar meal before collection will elevate yeast markers (arabinose). These confounders must be communicated clearly before collection.

Not a standalone diagnostic: The OAT does not diagnose specific diseases. Elevated quinolinic acid is not a diagnosis of neuroinflammation; elevated HPHPA is not a diagnosis of Clostridium infection. Results must be integrated with clinical history, symptom review, and complementary testing.

Requires practitioner interpretation: The density of the OAT report — 70+ markers across multiple pathways — makes it unsuitable for patient self-interpretation. Patterns matter more than individual markers; understanding pathway interconnections is essential for accurate clinical response.

Clinical Workflow: The OAT Within a Complete Functional Assessment

The OAT achieves its greatest clinical utility as part of an integrated testing strategy rather than as a standalone panel. The most informative complete gut-metabolic assessment combines:

Organic Acids Test (OAT): Metabolic by-product profile — mitochondrial, neurotransmitter, and dysbiosis signals from a metabolomics lens.

Comprehensive stool analysis (GI-MAP or equivalent): Direct microbial community assessment — qPCR identification of pathogens, commensals, and opportunistic organisms; mucosal immune markers (sIgA, zonulin, calprotectin); digestive function markers. Where the OAT tells you that dysbiosis is occurring via its metabolic footprint, the stool analysis tells you who is causing it. HPHPA on OAT plus Clostridia identification on stool PCR closes the diagnostic loop.

Serum B vitamins and methylation markers: Serum B12, folate, homocysteine, and — where indicated — MTHFR genotyping confirm or contextualise OAT nutrient cofactor findings. An elevated OAT methylmalonate alongside a serum B12 in the lower-normal range is a stronger clinical signal than either in isolation. Metabolic context matters here too: fasting insulin is a valuable adjunct when OAT shows elevated pyruvate, lactate, or Krebs cycle intermediates that may reflect insulin-driven mitochondrial substrate overload rather than a primary cofactor deficiency.

The oestrogen metabolism and gut health axis is also relevant to OAT interpretation: gut dysbiosis markers on the OAT — including bacterial phenol production reflected in benzoate and HPHPA — correlate directly with beta-glucuronidase-producing dysbiosis that drives enterohepatic oestrogen recirculation. The OAT becomes a valuable complementary panel for patients presenting with both gut dysfunction and hormonal imbalance.

Frequently Asked Questions

Q: How does the OAT compare to the GI-MAP — do I need both?

They assess different dimensions of the same gut ecosystem. The GI-MAP uses qPCR to directly identify and quantify microbial species in stool. The OAT captures the metabolic output of the gut microbiome (and the host's own metabolic pathways) via urine. In a well-resourced workup, both provide complementary information: the stool panel identifies who is there; the OAT shows what they are doing metabolically. For patients with limited testing budgets, the choice depends on clinical presentation — if the primary question is gut microbial community structure and pathogen identification, prioritise the GI-MAP; if the question is broader metabolic, mitochondrial, or neurotransmitter function, the OAT provides more.

Q: Can the OAT detect SIBO?

Not directly. Small intestinal bacterial overgrowth is formally diagnosed via lactulose or glucose breath testing measuring hydrogen and methane — the OAT does not replicate this. However, certain OAT findings are consistent with SIBO and gut dysbiosis: elevated HPHPA, arabinose, benzoic acid, and hippuric acid may all be elevated in SIBO contexts. The OAT metabolic picture can support clinical suspicion of SIBO and warrant breath test referral, but cannot substitute for breath testing.

Q: Are elevated mitochondrial markers always clinically significant?

Not invariably. Mildly elevated individual Krebs cycle intermediates may be within normal variation, particularly on a single collection. The pattern matters: a single mildly elevated succinate in an otherwise unremarkable OAT differs meaningfully from multiple elevated cycle intermediates across citrate, succinate, fumarate, and malate with elevated pyruvate and clinical fatigue symptoms. The latter warrants a mitochondrial support protocol; the former warrants reassessment with a repeat collection.

Q: How do I explain the OAT to a patient unfamiliar with metabolic testing?

A practical framing: the OAT is a metabolic fingerprint from your urine — it shows how efficiently your cells are producing energy, whether your gut microbes are producing any harmful by-products, whether your brain chemistry pathways have the raw materials they need, and whether your antioxidant and detoxification systems are under stress. It gives a map of body biochemistry that standard blood tests cannot provide, and helps target supplements and treatments precisely rather than guessing.

Q: Does diet before the test affect results?

Yes, meaningfully. A high-sugar meal before collection elevates yeast markers (arabinose). High-dose vitamin C within 48 hours falsely elevates oxalate markers. Recent antibiotic use suppresses microbial metabolite production. Standardising collection conditions — fasting from the night before, no vitamin supplements for 48 hours, first morning urine — is essential for clinically reliable results. The laboratory will provide specific instructions; these must be communicated clearly to patients before the kit is issued.

Key References

Shaw W. Organic Acids Test Interpretation: A Functional Medicine Approach. Great Plains Laboratory. 2015.
Shaw W. "Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia." Nutritional Neuroscience. 2010;13(3):135–143.
Frye RE, et al. "Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder." Translational Psychiatry. 2013;3:e220.
Bjørke-Monsen AL, Ueland PM. "Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to adolescence." Annual Review of Nutrition. 2003;23:401–422.
Koh A, et al. "From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites." Cell. 2016;165(6):1332–1345.
Brosnan JT, Brosnan ME. "The sulfur-containing amino acids: an overview." Journal of Nutrition. 2006;136(6):1636S–1640S.
Guilarte TR. "Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates." Frontiers in Aging Neuroscience. 2013;5:23.
Perkins MN, Stone TW. "An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid." Brain Research. 1982;247(1):184–187.
Roth W, et al. "Intestinal microbiota composition modulates choline bioavailability." mBio. 2021;12(2):e03012–20.

This article is intended for educational purposes and professional practice reference. It does not constitute individual medical advice. Clinical decisions should be made in the context of a full patient assessment by a qualified naturopath or integrative medicine practitioner. Functional testing results must be interpreted alongside clinical history and examination findings.